Humble hero or hidden villain? The ongoing story of aspirin's powers
The humble aspirin has a remarkable history dating back to ancient Egyptian times when the bark of weeping willow (which contains salicin from which the aspirin formulation is derived) was found to have anti-inflammatory properties. And Hippocrates wrote about the medicinal uses of white willow in the fifth century BC. But this story is not over yet.
This year marks another noteworthy chapter in the history of aspirin. A variety of articles about the medicine have attracted significant attention in both the scientific and lay press. Research and news stories have reported potential benefits of aspirin beyond preventing heart attacks and stroke, and re-emphasised bleeding risks.
One academic article provided an overview of individual patient data from seven randomised cardiovascular trials of four years or more in over 23,000 patients. It showed that death from all solid cancers was reduced overall by about 15 per cent by aspirin. The effect became significant after about five years and persisted to 20 years. Risk was unrelated to aspirin dose.
But it's important to note that two very large trials – the Women's Health Study and the Physician's Health Study – of almost 60,000 individuals followed up for 10-to-12 years were excluded because they tested alternate days rather than daily aspirin. In these trials, aspirin had no effect on cancer.
Other studies by the same researchers who published the meta-analysis showing aspirin's ability to protect against cancer also showed that the medicine had early short-term effects on cancer incidence and mortality and that metastatic spread (particularly of adenocarcinoma) was reduced by about 40 per cent to 50 per cent in a few years.
These observations add to previous studies suggesting aspirin may play a role in preventing gastrointestinal cancer, particularly in at-risk groups. We can only speculate about how this happens but platelets may be involved in cancer development by releasing growth factors and in metastatic spread by their role in the circulation.
Earlier this year, researchers published an updated meta-analysis of nine placebo-controlled trials of primary prevention for cardiovascular disease, involving over 100,000 people with an average age of 57 years. The paper attracted much more negative publicity than positive. It showed a greater number of non-trivial bleeds (30 per cent increase) than cardiovascular events prevented, mainly non-fatal heart attacks. Also, in contrast to the other papers, aspirin was found to have no effect on cancer mortality.
More recently, the bleeding risk has again been underscored by Italian research showing that the risk of major bleeds, such as intracranial haemorrhage and gastrointestinal bleeding, in real-life practice is five times more than in clinical trials.
So where does this leave practising clinicians?
In patients already diagnosed with coronary artery disease or those who've suffered a stroke, or have peripheral arterial disease, aspirin should be used with other proven secondary prevention therapies (providing bleeding risk is not considered prohibitive). In such contexts, aspirin reduces the risk of recurrent cardiovascular disease by about a quarter.
In those who are apparently healthy, cancer prevention is a very important possibility. But the evidence for taking aspirin daily as a cancer preventative is not considered sufficiently robust to warrant a population-wide recommendation for it to be used like this. The decision to do so should be made on an individual basis.
What's needed is more information for patients and doctors that can inform decision-making, particularly for the elderly and people with diabetes who don't have known cardiovascular disease. This is because both ageing and diabetes increase not only risk of heart problems and stroke but also bleeding. Increasing age and possibly diabetes also increase cancer risk.
Providing the kind of information that can help resolve this dilemma is exactly what we're hoping to do with the ASPREE study. The study involves 19,000 healthy people aged 70 and over and is designed to reliably address the net effects of aspirin. The primary endpoint of the study is healthy life years that might be impacted. It not only assesses quality of life, including cognition, but will also capture all effects of aspirin, both favourable and adverse.
Randomised trials eliminate the biases and confounding that often occur in population-based studies. The ASPREE study could have a major impact not only on the well-being of older Australians but globally. Just how much of a humble hero aspirin is, or whether it is, in fact, a villain because it causes bleeding, will hopefully soon be established.
More information: Readers can get more information about the ASPREE study online
Provided by Monash University
- Even low-dose aspirin may increase risk of GI bleeding Sep 12, 2011 | not rated yet | 0
- Benefits of aspirin more modest than previously believed Jan 16, 2012 | not rated yet | 0
- Study adds to evidence daily aspirin linked to lower cancer mortality Aug 10, 2012 | not rated yet | 0
- Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes Jul 05, 2011 | not rated yet | 0
- Report says new evidence could tip the balance in aspirin cancer prevention care Apr 09, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.
Medications May 17, 2013 | not rated yet | 0
Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...
Medications May 17, 2013 | 5 / 5 (1) | 0
(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...
Medications May 16, 2013 | 3.5 / 5 (2) | 0 |
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...
Medications May 15, 2013 | not rated yet | 0
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
1 hour ago | not rated yet | 0 |
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
1 hour ago | not rated yet | 0 |
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
2 hours ago | 5 / 5 (1) | 0 |
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
2 hours ago | 5 / 5 (1) | 0 |
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
1 hour ago | not rated yet | 0
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
6 hours ago | not rated yet | 0